Login to Your Account



Mesoblast's stem cell therapy shows durable outcomes in phase II

By Tamra Sami
Staff Writer

Tuesday, March 21, 2017

PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. is moving to phase III trials with its allogeneic mesenchymal precursor cell therapy to treat chronic low back pain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription